Zelenectide pevedotin

Phase 2Small molecule

Zelenectide pevedotin is one of 110 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

109

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Solid TumorNot yet recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Solid TumorPhase 2

Not yet recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Trodelvy

Gilead

Preclinical

37 3

Halaven

Eisai

Preclinical

38 4

Tykerb

GSK

Preclinical

80 5

Adriamycin

GGynecologic Oncology Group

Preclinical

87 6

Avastin

BBio-Thera Solutions

Preclinical

153 7

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 8

Prolia

Amgen

Preclinical

14 9

Gemzar

GGynecologic Oncology Group

Megace

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Breast Cancer

NCT06840483

Q1 2029

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT06933329

Q2 2030

Phase 2Not yet recruiting

Solid Tumor

NCT07681674

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting·BBicycleTx Limited·Phase 2·NCT06933329·73 enrolled

Breast Cancer1 trial

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

Recruiting·BBicycleTx Limited·Phase 2·NCT06840483·66 enrolled

Solid Tumor1 trial

Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product on a BicycleTx Limited-Sponsored Study

Not yet recruiting·BBicycleTx Limited·Phase 2·NCT07681674·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Zelenectide pevedotin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zelenectide pevedotin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zelenectide pevedotin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BicycleTx Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBicycleTx Limited

Zelenectide pevedotin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q1 2029

Q2 2030

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Breast Cancer1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News